In parallel, TGF-β promotes tumour progression by driving epithelial–mesenchymal transition (EMT), stimulating angiogenesis [25], and activating cancer-associated fibroblasts (CAFs), which enhance extracellular matrix (ECM) deposition and form physical barriers to immune cell infiltration [26,27,28]. The gene discussed is TGFB1; the disease is cancer.